Cevena secures funding for heart health product

Related tags Nutrition

Canada's Cevena Bioproducts has secured C$6 million in venture
capital funding, which it says will ensure the successful
commercialization of its Viscofiber beta-glucan concentrate,
reports Jess Halliday.

Viscofiber, Cevena's​ lead product, is derived from fibrous cell walls of either oats (50 percent concentrate) or barley (60 percent concentrate) using a patented fermentation technology for which it has been granted an exclusive worldwide license by the University of Alberta.

The company claims it is the richest beta-glucan material available, 20 to 30 times more viscous than the next leading concentrates, since the structure of the natural grain is not altered during the fermentation process. Viscosity is understood to be the main property responsible for soluble fiber's ability to lower blood lipids.

Two independent clinical trials into the efficacy of Viscofiber in addressing healthy cholesterol levels and maintaining healthy glycemic response, carried out at the University of Toronto, have yielded positive results but have not yet been published.

Further research is also planned to investigate its efficacy for gastrointestinal health and satiety.

Viscofiber was launched in March and in May the company announced the opening of a sales office in Chicago, to sell the product to food and dietary supplement makers in the United States.

The latest financing was led by the Business Development Bank of Canada's Venture Capital Group, which was joined by the Golden Opportunities Fund and existing investors Technologies Limited Partnership and AVAC, Ltd.

Company president and CEO Kimmo Lucas said the investors "were chosen based upon their expertise in the agri-food/supplement area as well as the synergies they bring to Cevena Bioproducts and our flagship technology employed to produce… Viscofiber."

Last month VP of sales & new business development Richard Staack told NutraIngredients-USA.com that some large deals with food and supplements manufacturers are currently under negotiation and may come to fruition within the next month or two.

As for the medium long-term, Staack said: "We are hopefully going to be the leading soluble fiber on the market within 12 to 24 months."

Related topics Cardiovascular health

Related news

Related products

Kalita®: taking bergamot extract to the next level

Kalita®: taking bergamot extract to the next level

Content provided by Giellepi SpA | 04-Apr-2023 | White Paper

Due to its cardiometabolic benefits, a number of bergamot extracts have been manufactured over the years using different extraction technologies aimed...

Related suppliers

Follow us


View more